These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25438027)

  • 1. Predictors of placebo response in bipolar depression.
    Nierenberg AA; Østergaard SD; Iovieno N; Walker RS; Fava M; Papakostas GI
    Int Clin Psychopharmacol; 2015 Mar; 30(2):59-66. PubMed ID: 25438027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between placebo response rate and clinical trial outcome in bipolar depression.
    Iovieno N; Nierenberg AA; Parkin SR; Hyung Kim DJ; Walker RS; Fava M; Papakostas GI
    J Psychiatr Res; 2016 Mar; 74():38-44. PubMed ID: 26736040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
    Papakostas GI; Martinson MA; Fava M; Iovieno N
    J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.
    Tedeschini E; Fava M; Goodness TM; Papakostas GI
    Eur Neuropsychopharmacol; 2010 Aug; 20(8):562-7. PubMed ID: 20219330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How informative are open-label studies for youth with bipolar disorder? A meta-analysis comparing open-label versus randomized, placebo-controlled clinical trials.
    Biederman J; Petty CR; Woodworth KY; Lomedico A; O'Connor KB; Wozniak J; Faraone SV
    J Clin Psychiatry; 2012 Mar; 73(3):358-65. PubMed ID: 22154898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bipolar depression: a new role for atypical antipsychotics?
    Keck PE
    Bipolar Disord; 2005; 7 Suppl 4():34-40. PubMed ID: 15948765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Levkovitz Y; Ameral VE; Papakostas GI
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):289-96. PubMed ID: 21557881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials.
    Vita A; De Peri L; Sacchetti E
    J Clin Psychopharmacol; 2011 Oct; 31(5):613-24. PubMed ID: 21869691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the placebo response in antidepressant trials.
    Rief W; Nestoriuc Y; Weiss S; Welzel E; Barsky AJ; Hofmann SG
    J Affect Disord; 2009 Nov; 118(1-3):1-8. PubMed ID: 19246102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nature of placebo response in clinical studies of major depressive disorder.
    Papakostas GI; Østergaard SD; Iovieno N
    J Clin Psychiatry; 2015 Apr; 76(4):456-66. PubMed ID: 25700292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M;
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.
    Stamm TJ; Lewitzka U; Sauer C; Pilhatsch M; Smolka MN; Koeberle U; Adli M; Ricken R; Scherk H; Frye MA; Juckel G; Assion HJ; Gitlin M; Whybrow PC; Bauer M
    J Clin Psychiatry; 2014 Feb; 75(2):162-8. PubMed ID: 24345793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.